← Leaderboards
Douglas R Martin
Auburn University At Auburn
$3,447,411
Attributed
$8,285,240
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,285,240 · 4
By mechanism
R01$8,285,240 · 4
Top collaborators
- Miguel S Esteves14 shared
- Heather L Gray-Edwards5 shared
- Thomas J. Meade5 shared
Most similar at Auburn University At Auburn
Same institution · by research overlap
- Heather L Gray-Edwards$4,340,720
- Henry J. Baker$898,542
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyDisease ProgressionDoseBrainEnzymesLysosomal Storage DiseasesMagnetic Resonance ImagingCapsidFelis CatusOrganAnimal ModelCellsNervous System DisorderNeuraxisSandhoff DiseaseBeta-N-AcetylhexosaminidaseProductionSafetyAffectHemophilia APrevalenceInfantIn VivoGanglioside Gm1
Grant awards (15)
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$548,624
R01 · FY2024 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$659,071
R01 · FY2023 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$655,861
R01 · FY2022 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$645,047
R01 · FY2021 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$629,733
R01 · FY2020 · NS
Whole-body therapy for GM2 gangliosidoses$536,121
R01 · FY2020 · NS · contact PI
Whole-body therapy for GM2 gangliosidoses$584,327
R01 · FY2019 · NS · contact PI
Whole-body therapy for GM2 gangliosidoses$589,446
R01 · FY2018 · NS · contact PI
Whole-body therapy for GM2 gangliosidoses$599,714
R01 · FY2017 · NS · contact PI
Whole-body therapy for GM2 gangliosidoses$630,300
R01 · FY2016 · NS · contact PI
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$493,126
R01 · FY2013 · HD
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$506,598
R01 · FY2012 · HD
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$501,435
R01 · FY2011 · HD
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$527,087
R01 · FY2010 · HD
Stromal Stem Cells for Therapy of the Gangliosidoses$178,750
R01 · FY2004 · HL